Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.32 (
phosphoenolpyruvate carboxykinase
)
4,204
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We showed recently that apoA-IV improves glucose homeostasis by enhancing pancreatic insulin secretion in the presence of elevated levels of glucose. Therefore, examined whether apolipoprotein A-IV (apoA-IV) also regulates glucose metabolism through the suppression of hepatic gluconeogenesis. The ability of apoA-IV to lower gluconeogenic gene expression and glucose production was measured in apoA-IV(-/-) and wild-type mice and primary mouse hepatocytes. The transcriptional regulation of Glc-6-Pase and
phosphoenolpyruvate carboxykinase
(
PEPCK
) by apoA-IV was determined by luciferase activity assay. Using bacterial two-hybrid library screening,
NR1D1
was identified as a putative apoA-IV-binding protein. The colocalization and interaction between apoA-IV and
NR1D1
were confirmed by immunofluorescence, in situ proximity ligation assay, and coimmunoprecipitation. Enhanced recruitment of
NR1D1
and activity by apoA-IV to Glc-6-Pase promoter was verified with ChIP and a luciferase assay. Down-regulation of apoA-IV on gluconeogenic genes is mediated through
NR1D1
, as illustrated in cells with
NR1D1
knockdown by siRNA. We found that apoA-IV suppresses the expression of
PEPCK
and Glc-6-Pase in hepatocytes; decreases hepatic glucose production; binds and activates nuclear receptor
NR1D1
and stimulates
NR1D1
expression; in cells lacking
NR1D1
, fails to inhibit
PEPCK
and Glc-6-Pase gene expression; and stimulates higher hepatic glucose production and higher gluconeogenic gene expression in apoA-IV(-/-) mice. We conclude that apoA-IV inhibits hepatic gluconeogenesis by decreasing Glc-6-Pase and
PEPCK
gene expression through
NR1D1
. This novel regulatory pathway connects an influx of energy as fat from the gut (and subsequent apoA-IV secretion) with inhibition of hepatic glucose production.
...
PMID:Apolipoprotein A-IV reduces hepatic gluconeogenesis through nuclear receptor NR1D1. 2431 88